Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cormedix ( (CRMD) ) has shared an announcement.
On March 6, 2026, CorMedix, Inc. released an updated investor presentation outlining its institutional-focused pharmaceutical portfolio and reaffirmed its previously issued sales guidance for DefenCath in 2027. The company corrected an inadvertent lower range mentioned on its March 5, 2026 earnings call and reiterated that it expects full-year 2027 DefenCath sales to fall between $100 million and $140 million, underscoring management’s confidence in the product’s growth trajectory.
The presentation also highlighted CorMedix’s broader growth and financial outlook, including 2026 company-wide revenue guidance of $300 million to $320 million and adjusted EBITDA of $100 million to $125 million, supported by DefenCath and a suite of anti-infective and cardiovascular products. For investors and other stakeholders, the reaffirmed guidance and detailed projections signal continued emphasis on DefenCath as a key revenue driver within a diversified hospital and acute-care platform, while clarifying any confusion created by the prior earnings call commentary.
The most recent analyst rating on (CRMD) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
The score is driven primarily by the sharp improvement in 2025 financial performance (profitability and cash generation), offset by elevated forward uncertainty from reimbursement-driven DEFENCATH price pressure and guided sales declines. Technicals are a notable drag due to a clear downtrend, while valuation is supportive given the low P/E but appears to reflect the same durability risks highlighted in guidance.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Therapeutics is a commercial pharmaceutical company focused on providing innovative products for institutional markets, with a diversified portfolio of specialty injectable therapies, including DefenCath and multiple anti-infective drugs. Its products are sold to more than 500 hospitals, infusion centers and clinics, and the company targets growth through organic expansion, label extensions and bolt-on acquisitions.
The company reports a scalable commercial platform with eight diversified products and a growing financial profile, highlighted by pro forma 2025 net revenue of $401 million and guidance for 2026 revenue of $300 million to $320 million and adjusted EBITDA of $100 million to $125 million. CorMedix also maintains a presence on the Nasdaq Global Market and holds $149 million in cash and short-term investments against $150 million in convertible debt as of December 31, 2025.
Average Trading Volume: 2,860,382
Technical Sentiment Signal: Sell
Current Market Cap: $496.4M
Learn more about CRMD stock on TipRanks’ Stock Analysis page.